Disaggregated Revenues

6 Months Ended

Jun. 30, 2023

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
	(unaudited)				(unaudited)
Net product sales
Qelbree	$	30,977	$	11,099	$	56,759	$	19,382
GOCOVRI	28,751		24,700		54,761		47,301
Oxtellar XR	23,800		29,958		52,715		57,479
Trokendi XR	19,319		71,602		54,109		134,434
APOKYN	17,605		20,447		34,814		38,895
Other(1)	7,884		7,653		15,753		15,432
Total net product sales	$	128,336	$	165,459	$	268,911	$	312,923
Royalty revenues	7,227		4,592		20,416		9,634
Total revenues	$	135,563	$	170,051	$	289,327	$	322,557

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

The decrease in Trokendi XR net product sales for the three and six months ended June 30, 2023, compared to the same period in 2022 was primarily attributable to the loss of exclusivity with generic entrants in January 2023.

The following table shows the percentage of net product sales to total net product sales:

	Percentage of Net Product Sales
	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Qelbree	24%	7%	21%	6%
GOCOVRI	22%	15%	20%	15%
Oxtellar XR	19%	18%	20%	18%
Trokendi XR	15%	43%	20%	43%
APOKYN	14%	12%	13%	12%
Other(1)	6%	5%	6%	6%
Total	100%	100%	100%	100%

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total net product sales and collectively accounted for more than 75% of our total net product sales for the three and six months ended June 30, 2023 and 2022.

The Company recognized noncash royalty revenue of $1.7 million and $4.0 million for the three and six months ended June 30, 2023, respectively. The Company recognized noncash royalty revenue of $2.5 million and $4.7 million for the three and six months ended June 30, 2022, respectively. Refer to Note 15, Commitments and Contingencies.